Alps Advisors Inc. Has $1.87 Million Stake in Epizyme Inc (NASDAQ:EPZM)

Alps Advisors Inc. reduced its stake in Epizyme Inc (NASDAQ:EPZM) by 4.5% in the 3rd quarter, Holdings Channel reports. The firm owned 181,550 shares of the biopharmaceutical company’s stock after selling 8,575 shares during the period. Alps Advisors Inc.’s holdings in Epizyme were worth $1,873,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Epizyme by 29.9% in the 2nd quarter. Vanguard Group Inc. now owns 7,078,470 shares of the biopharmaceutical company’s stock worth $88,835,000 after purchasing an additional 1,630,171 shares during the last quarter. BlackRock Inc. lifted its holdings in Epizyme by 31.8% in the 2nd quarter. BlackRock Inc. now owns 6,440,597 shares of the biopharmaceutical company’s stock worth $80,831,000 after purchasing an additional 1,552,216 shares during the last quarter. FMR LLC lifted its holdings in Epizyme by 0.3% in the 1st quarter. FMR LLC now owns 3,484,137 shares of the biopharmaceutical company’s stock worth $43,169,000 after purchasing an additional 11,759 shares during the last quarter. Rock Springs Capital Management LP lifted its holdings in Epizyme by 5.5% in the 2nd quarter. Rock Springs Capital Management LP now owns 1,850,100 shares of the biopharmaceutical company’s stock worth $23,219,000 after purchasing an additional 96,725 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in Epizyme by 2.6% in the 2nd quarter. Victory Capital Management Inc. now owns 1,680,830 shares of the biopharmaceutical company’s stock worth $21,094,000 after purchasing an additional 43,360 shares during the last quarter. Hedge funds and other institutional investors own 86.32% of the company’s stock.

EPZM opened at $15.18 on Friday. The company has a current ratio of 10.90, a quick ratio of 10.90 and a debt-to-equity ratio of 0.03. The stock has a market cap of $1.34 billion, a PE ratio of -8.83 and a beta of 2.40. The stock’s 50 day simple moving average is $10.98 and its 200-day simple moving average is $12.39. Epizyme Inc has a 1 year low of $5.14 and a 1 year high of $16.59.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.11. The company had revenue of $5.72 million for the quarter, compared to analyst estimates of $5.50 million. Epizyme had a negative return on equity of 49.38% and a negative net margin of 468.53%. Equities analysts forecast that Epizyme Inc will post -1.89 earnings per share for the current fiscal year.

Several equities research analysts recently weighed in on EPZM shares. ValuEngine lowered Epizyme from a “hold” rating to a “sell” rating in a report on Thursday. Zacks Investment Research lowered Epizyme from a “hold” rating to a “sell” rating and set a $11.00 target price for the company. in a report on Monday, October 21st. BidaskClub upgraded Epizyme from a “sell” rating to a “hold” rating in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating on shares of Epizyme in a research report on Thursday, October 31st. Finally, Cowen reaffirmed a “buy” rating and issued a $18.00 price target on shares of Epizyme in a research report on Thursday, October 31st. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $17.50.

Epizyme Profile

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

Further Reading: How dollar cost averaging works

Want to see what other hedge funds are holding EPZM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Epizyme Inc (NASDAQ:EPZM).

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.